Cout réel de la prise en charge des cancers du col de l'utérus en radiothérapie au Cameroun / The real cost of the management of cervical cancers by radiotherapy in Cameroon

Introduction. Le cancer du col utérin est le deuxième cancer de la femme au Cameroun. La radiothérapie reste une des modalités thérapeutiques phares dans la prise en charge de cette pathologie et l'État participe en y apportant une subvention. Toutefois, plusieurs patientes n'accèdent pas au traitement en raison des difficultés financières. Notre objectif était d'évaluer le coût réel de la prise en charge afin de servir de support aux politiques d'aide aux patientes. Méthodologie. Uneétude descriptive, transversale portant sur les patientes traitées en radiothérapie à l'Hôpital Général de Douala pour cancer du col de l'utérus a été réalisée d'octobre 2020 à janvier 2021.Résultats. Au total 35 dossiers de patientes ont été inclus. Lespatientes avaient de faibles revenus (<108.810 XAF /mois, 51,3%), étaient sans assurance maladie (88,6%), provenant en majorité des villes hors de Douala (54,3%), avec des cancers localement évolués. Le coût global moyen du traitement était de 511 264 XAF+/-103479 XAF (779,42 +/-157,75 euros) pour chaque patiente. La durée moyenne de traitement était de 57,34 jours, avec un nombre médian de 27 séances. Les frais supplémentaires pendant le traitement provenaient de la chimiothérapie, de la gestion des effets secondaires, notamment des transfusions sanguines, et du bilan de suivi. Plus de la moitié des patientes ont eu besoin d'une prise en charge supplémentaire par chimiothérapie ou chirurgie. Conclusion. La prise en charge du cancer du col utérin par radiothérapie est coûteuse et peu accessible à la majorité des patientes Camerounaises.

Introduction.Cervix cancer is the second cancer among women in Cameroon. Radiotherapy is often warranted in its management. Many patients do not access treatment due to financial difficulties. Our objective was to assess the real cost of care in order to support patient assistance policies. Methodology. A descriptive cross over study of women treated by radiotherapy at the Douala General Hospital from October 2020 to January 2021 was conducted. Results. A total number of 35 patient files were included in the study. Patients generally had low income (<108.810 XAF /month), without medical insurance, lived out of Douala, and were diagnosed at locally advanced stages of their disease. Average cost of treatment for radiotherapy alone was 511,264 XAF +/-103,479 XAF. Average duration of treatment was 57.34 days, with a median number of 27 sessions. Extra cost came from chemotherapy, management of side effects especially from blood transfusions, and imaging. More than half of the patients required additional expense for adjunct chemotherapy or surgery. Conclusion. The total cost of treatment for cervix cancer by radiotherapy is quite expensive, and not accessible to the average Cameroonian

Carga de la enfermedad y costos en salud por la exposición a mercurio: revisión de alcance / Burden of disease and health costs from mercury exposure: Scoping review

Resumen Introducción: El mercurio circula por el aire; persiste en suelos, sedimentos y agua, y causa efectos en la salud humana. Las mujeres en edad fértil y los neonatos son la población más vulnerable. Objetivo: Analizar las evidencias sobre la carga de enfermedad ocasionada por la exposición a mercurio, así como el impacto económico sobre el sistema de salud. Metodología: Revisión de alcance de la literatura, de las bases de datos PUBMED y EPISTEMONIKOS, búsqueda manual de documentos técnicos de entidades oficiales de diferentes continentes. Resultados: Se identificaron 311 registros en bases de datos y 4 en búsqueda manual en entidades oficiales; 19 artículos fueron incluidos. Discusión: Predomina la afectación del desarrollo neurológico y cognitivo en niños de madres expuestas y lactantes. Los costos se midieron por la pérdida del coeficiente intelectual. Conclusión: Efectos en salud por la exposición a metilmercurio se traducen en gastos para la sociedad y los sistemas de salud.

Abstract Introduction: Mercury circulates through the air, persists in soils, sediments and water, and can affect human health. Women of childbearing age and newborns are the most vulnerable population. Objective: To analyze the evidence on the burden of disease caused by mercury exposure, as well as the economic impact on the health system. Methodology: Review of the literature, PUBMED and EPISTEMONIKOS databases, manual search of technical documents of official entities from different continents. Results: A total of 311 records were identified in databases and four in manual searches from official entities; 19 articles were included. Discussion: Neurological and cognitive development in children of exposed mothers and infants are more predominant. Costs were measured by IQ loss. Conclusion: Health effects of methylmercury exposure translate into costs for society and health systems.

Análisis del impacto presupuestal en Colombia de la prueba de HPV con genotipificación comparada con la citología / Budget impact analysis of primary screening with the HPV test and genotyping against conventional cytology in Colombia

Introducción. La detección del virus del papiloma humano mediante la combinación de la prueba de HPV y otras técnicas como la citología, ha demostrado su eficacia en el diagnóstico y tratamiento oportuno de lesiones asociadas con el cáncer de cuello uterino. Objetivo. Estimar el impacto presupuestal de la estrategia de detección temprana del HPV mediante la prueba de genotipificación combinada con la citología en comparación con la citología convencional, en mujeres de 30 a 65 años participantes en el programa de tamizaje de cáncer de cuello uterino en una Entidad Administradora del Plan de Beneficios en salud (EAPB) en Colombia. Materiales y métodos. Utilizando un árbol de decisiones y un modelo de Markov, se estimaron las implicaciones clínicas y los costos directos anuales de dos ciclos de tamizaje, diagnóstico y tratamiento, en una cohorte de mujeres. Las prevalencias de los resultados clínicos y los costos se tomaron de la base de datos de una EAPB y la información de la progresión, persistencia y regresión de los estados de salud provinieron del estudio ATHENA. Resultados. El esquema de tamizaje con la prueba de HPV, la genotipificación y la citología resultó en un ahorro de costos comparado con la citología convencional. El costo promedio por ciclo de tamizaje con la prueba de HPV se estimó en COP $129'201.363 y con la citología en COP $186'309.952, es decir, un ahorro de COP $57'108.589 (30,7 %). Conclusión. La implementación de la estrategia de tamizaje evaluada sugiere que habría ahorros derivados de la detección temprana de los estados de salud asociados con el desarrollo de cáncer de cuello uterino.

Introduction: The detection of the human papillomavirus (HPV) through the combination of the HPV test and other techniques such as cytology has impacted the detection and timely treatment of lesions associated with cervical cancer. Objective: To estimate the budgetary impact of the strategy of early detection of HPV with DNA test genotyping with reflex cytology versus conventional cytology in women aged 30 to 65 years attending the cervical cancer screening program at a health benefit managing entity in Colombia. Materials and methods: Using a decision tree and a Markov model, the clinical implications and direct costs of screening, diagnosis, and treatment were estimated in a cohort of women. The analysis considered two screening cycles and their annual costs. The data on the prevalence of clinical results and the costs were taken from the health managing entity. The information on the progression, persistence, and regression of the health states were taken from the ATHENA study. Results: The screening scheme with the HPV test, genotyping, and reflex cytology compared to conventional cytology was cost-saving. The average cost per screening cycle with the HPV test was estimated at COP $ 129,201,363 and with cytology at COP $ 186,309,952, i.e., a saving of COP $ 57,108,589 (30.7%). Conclusion: The implementation of the screening strategy under evaluation suggests prospective savings derived from the early detection of health states associated with the development of cervical cancer.

A pandemia de COVID-19 e o seu impacto à saúde planetária / The COVID-19 pandemic and its impact on planetary health

A pandemia de COVID-19 deu ao mundo uma imagem clara do que é uma crise multidimensional em escala planetária, revelando o papel central que ocupa o setor de saúde e as profundas desigualdades no acesso aos cuidados em saúde que existem entre os diferentes países, e dentro de cada um deles. Melhorar os efeitos ambientais do setor e reduzir as emissões de gases de efeito estufa pode não apenas melhorar a saúde de todos, mas também reduzir os custos com os cuidados em saúde. O setor de saúde de cada país libera direta e indiretamente gases de efeito estufa ao fornecer seus serviços e ao comprar produtos, serviços e tecnologias em uma cadeia de fornecimento de carbono intensivo. Educar os profissionais de saúde mais profundamente sobre os efeitos das mudanças climáticas pode levar a práticas clínicas mais sustentáveis, melhorando os resultados para os pacientes e fornecendo um impulso substancial para aumentar os esforços para reduzir as emissões de carbono. O setor da saúde deve assumir a responsabilidade por sua pegada climática respondendo à crescente emergência climática, não apenas prestando assistência aos doentes, feridos ou moribundos como resultado da crise climática e suas causas, mas também fazendo a prevenção primária e reduzindo drasticamente suas próprias emissões.

The COVID-19 pandemic has painted a clear picture of what a multidimensional planetary crisis is, revealing the central role played by the health sector and the deep inequalities in access to health care that exist between and within each country. Decreasing the environmental effects of the health sector and reducing greenhouse gas emission may not only improve people's health, but also reduce health care costs. The health care sectors around the world directly and indirectly release greenhouse gases by providing their services and purchasing products, services, and technologies within a carbon-intensive supply chain. Further educating health care professionals about the effects of climate change may lead to more sustainable clinical practices, improving patient outcomes and providing substantial impetus to increased efforts to reduce carbon emission. The health sector must take responsibility for its climate footprint by responding to the growing climate emergency not only by assisting the sick, injured, or dying from the climate crisis, but also by doing primary prevention and drastically reducing its own carbon emission.

Costo de atención de recién nacidos con peso 1500 gramos en el Hospital Penna, Bahía Blanca, Argentina / Costs for the health care of newborns weighing up to 1500 g at Penna Hospital, Bahía Blanca, Argentina

INTRODUCCIÓN: Los sistemas de costos por servicio hospitalario permiten evaluar la eficiencia en la utilización de recursos y son la base para realizar estudios comparativos entre grupos de pacientes con características diferenciales. La internación en Neonatología de niños de bajo peso al nacer presenta especial interés por su complejidad y alto costo. El objetivo fue estimar los costos directos del día de internación en el Servicio de Neonatología del Hospital Interzonal Dr. José Penna de pacientes con peso al ingreso menor o igual a 1500 g en 2019. MÉTODOS: Se realizó un estudio retrospectivo, para el cual se relevaron datos del Servicio de Neonatología y de las áreas de compras y personal del Hospital. Se estimó el costo promedio por día de internación y por egreso del total del Servicio y de los recién nacidos con peso de hasta 1500 g. RESULTADOS: El estudio se realizó sobre 489 egresos. El costo directo promedio por día de internación fue de $17.755. Para el grupo de peso ≤ 1500 g, el promedio de días de internación fue de 55,9 y el costo promedio por egreso, de $992.191; para ≤ 1000 g, de 80,6 y $1.430.229, respectivamente. Se evidenció un fuerte impacto del bajo peso al nacer: el 8% de los egresos con vida de Neonatología genera el 33% de los costos del proceso de internación neonatal. DISCUSIÓN: Es importante realizar estudios de costos por servicio hospitalario, en especial por grupos de casos, a fin de generar información útil para la toma de decisiones.

Aspects socio-économiques de la prise en charge des hépatites virales chroniques en Côte-d'Ivoire / Socio-economic aspects of the management of chronic viral hepatitis in Côte-d'Ivoire

Contexte et objectifs. Les hépatites virales chroniques constituent un problème de santé publique en Côte-d'Ivoire. Très peu de malades accèdent au traitement en raison des coûts élevés du bilan et du traitement. L'objectif de la présente étude était d'évaluer les coûts du bilan et du traitement des hépatites virales chroniques. Méthodes. Il s'agissait d'une étude observationnelle transversale analytique réalisée, du 1er mars 2019 au 31 juillet 2019, en consultation d'hépato-gastroentérologie du CHU de Yopougon. Les variables étudiées étaient les paramètres sociodémographiques et économiques. Résultats. Au total, 136 patients (hommes 53, 6 %, âge moyen de 42 ans ± 12,2) ont été inclus. Plus de la moitié des patients (63,3 %) avaient un revenu mensuel n'excédant pas 490.39 USD. Le coût du bilan initial était de 223.13 USD et de 351.14 USD respectivement, pour l'hépatite virale B et C. Le ténofovir et l'interféron pégylé étaient gratuits. Le traitement par sofosbuvir + velpastavir coûtait 593.37 USD. Le bilan de suivi annuel était estimé à 237.02 USD pour l'hépatite virale B, 225.58 USD pour l'hépatite virale C. Conclusion. Le bilan et le traitement des hépatites virales chroniques ont un coût prohibitif pour les patients malgré la couverture maladie universelle.

Context and objectives. Chronic viral hepatitis is a public health problem in Côte-d'Ivoire. A significant number of patients have little access to treatment due to the high costs of assessment and treatment. The objective of our study was to evaluate the costs of assessments and treatment of chronic viral hepatitis. Methods. This was an analytical cross-sectional observational study from March 1, 2019 to July 31, 2019 in the HepatoGastroenterology Consultation Service at the Yopougon University Hospital. The variables studied were socio-demographic and economic parameters. Results. 136 patients (men 53.6 %, average age 42 ± 12.2 years) were included. More than half of the patients (63.3 %) had a monthly income not exceeding 490.39 USD. The cost of the initial assessment was 223.13 USD and 351.14 USD for viral hepatitis B and C, respectively. Tenofovir and pegylated interferon were free of charge. Treatment with sofosbuvir + velpastavir cost 593.37 USD. The annual follow-up assessment was estimated at 237.02 USD for viral hepatitis B and 225.58 USD for viral hepatitis C. Conclusion. The assessment and treatment of chronic viral hepatitis have a cost that remains high for patients despite the universal health coverage.

Average direct costs of outpatient, hospital, and home care provided to patients with chronic wounds / Costos directos promedios de la atención ambulatoria, hospitalaria y domiciliaria prestada a pacientes con heridas crónicas / Custos diretos médios da assistência ambulatorial, hospitalar e domiciliar prestada aos pacientes com feridas crônicas

ABSTRACT Objective: To analyze the average direct costs of outpatient, hospital, and home care provided to patients with chronic wounds. Method: Quantitative, exploratory-descriptive case study, carried out in a Comprehensive Wound Care Unit. Costs were obtained by multiplying the time spent by professionals by the unit cost of labor in the respective category, adding to the costs of materials and topical therapies. Results: Outpatient care costs corresponded to US$4.25 (SD ± 7.60), hospital care to US$3.87 (SD ± 17.27), and home care to US$3.47 (SD ± 5.73). In these three modalities, direct costs with dressings and medical consultations were the most representative: US$7.76 (SD ± 9.46) and US$6.61 (SD ± 6.54); US$7.06 (SD ± 24.16) and US$15.60 (SD ± 0.00); US$4.09 (SD ± 5.28) and US$15.60 (SD ± 0.00), respectively. Conclusion: Considering comprehensive care for patients with chronic wounds, the mean total direct cost was US$10.28 (SD ± 17.21), with the outpatient modality being the most representative in its composition. There was a statistically significant difference (p value = 0.000) between the costs of home and outpatient, home and hospital, and outpatient and hospital care.

RESUMEN Objetivo: Analizar los costos directos promedios de la atención ambulatoria, hospitalaria y domiciliaria prestada a pacientes con heridas crónicas. Método: Investigación cuantitativa, exploratoria-descriptiva, del tipo estudio de caso, realizada en una Unidad de Atención Integral de Heridas. Los costos se obtuvieron al multiplicar el tiempo dedicado por los profesionales por el costo unitario de la mano de obra en la respectiva categoría, sumado a los costos de materiales y terapias tópicas. Resultados: Los costos de atención ambulatoria correspondieron a US$ 4,25 (DE ± 7,60), hospitalaria a US$ 3,87 (DE ± 17,27) y atención domiciliaria a US$ 3,47 (DE ± 5,73). En estas tres modalidades, los costos directos con apósitos y consultas médicas fueron los más representativos: US$7,76 (DE ± 9,46) y US$6,61 (DE ± 6,54); US$7,06 (DE ± 24,16) y US$15,60 (DE ± 0,00); US$4,09 (DE ± 5,28) y US$15,60 (DE ± 0,00), respectivamente. Conclusión: Considerando la atención integral a pacientes con heridas crónicas, el costo directo promedio total fue de US$ 10,28 (DE ± 17,21), siendo la modalidad ambulatoria la más representativa en su composición. Hubo una diferencia estadísticamente significativa (p-valor = 0,000) entre los costos de atención domiciliaria y ambulatoria; domiciliaria y hospitalaria y, por fin, ambulatoria y hospitalaria.

RESUMO Objetivo: Analisar os custos diretos médios da assistência ambulatorial, hospitalar e domiciliar prestada aos pacientes com feridas crônicas. Método: Pesquisa quantitativa, exploratório-descritiva, do tipo estudo de caso, realizada numa Unidade de Tratamento Integral de Ferida. Obtiveram-se os custos multiplicando-se o tempo despendido pelos profissionais pelo custo unitário da mão de obra da respectiva categoria, somando-se aos custos dos materiais e terapias tópicas. Resultados: Os custos da assistência ambulatorial corresponderam a US$4,25 (DP ± 7,60), da hospitalar a US$3,87 (DP ± 17,27) e da domiciliar a US$3,47 (DP ± 5,73). Nessas três modalidades, os custos diretos com os curativos e consultas médicas foram os mais representativos: US$7,76 (DP ± 9,46) e US$6,61 (DP ± 6,54); US$7,06 (DP ± 24,16) e US$15,60 (DP ± 0,00); US$4,09 (DP ± 5,28) e US$15,60 (DP ± 0,00), respectivamente. Conclusão Considerando a assistência integral aos pacientes com feridas crônicas, o custo direto médio total foi de US$10,28 (DP ± 17,21), sendo a modalidade ambulatorial a mais representativa na sua composição. Constatou-se diferença estatística significante (valor p = 0,000) entre os custos da assistência domiciliar e ambulatorial, domiciliar e hospitalar e ambulatorial e hospitalar.

Modelo de estimación de costos de atención integral para enfermedades trasmisibles / Comprehensive care cost estimation model for communicable diseases

Los costos de atención integral para enfermedades trasmisibles, en el régimen subsidiado o contributivo indirecto del sistema de salud del Perú., son la base para la formulación de políticas publicas para garantizar el derecho a la salud, por esto, mediante un arreglo metodologico, se construyo un modelo de estimación de costos de atención integral para enfermedades trasmisibles, el cual, es verificación y validación por expertos. Primero se priorizaron dengue, malaria, tuberculosis y enfermedad diarreica aguda como grupos de diagnósticos, de acuerdo a aspectos demográficos, determinantes sociales, indicadores de mortalidad y morbilidad. Sucesivamente se construye el modelo teorico "Costo Atención Integral (CAI) = Æ© C (Capital)+ CVI (Costo variable indireccto) + CVD (Costo variable direccto) +CC (Costo por contingencia) + CP/S (Costo paciente/sociedad), obteniendo valores estimados de 3,66+0,40 y 3,71+0,34 respectivamente para costos totales; mientras que el costo paciente/sociedad arrojaron valores de 2,98+0,49 de verificación y validación de 2,68+0,32; estimaciones indicativas que los componentes del sistema propuesto pesquisan los costos reales de los procesos de atención se salud del régimen sidsidiario, es decir alta adecuación de los procesos, utilidad de insumos y materiales, uso eficiente en los diferentes entornos del sistema; como una herramienta crucial de información para la comparación e identificación de las intervenciones de tipo preventivo más costo-efectivas(AU)

The costs of comprehensive care for communicable diseases, in the subsidized or indirect contributory regimen of the Peruvian health system, are the basis for the formulation of public policies to guarantee the right to health, for this reason, through a methodological arrangement, it was built a comprehensive care cost estimation model for communicable diseases, which is verified and validated by experts. First, dengue, malaria, tuberculosis and acute diarrheal disease were prioritized as diagnostic groups, according to demographic aspects, social determinants, mortality and morbidity indicators. Successively, the theoretical model "Comprehensive Care Cost (CCI) = Æ© C (Capital) + IVC (Indirect variable cost) + DVC (Direct variable cost) + CC (Contingency cost) + P/SC (Patient/society cost) is built , obtaining estimated values of 3.66+0.40 and 3.71+0.34 respectively for total costs; while the patient/society cost yielded values of 2.98+0.49 for verification and validation of 2.68+0.32; indicative estimates that the components of the proposed system investigate the real costs of the health care processes of the subsidiary regime, that is to say, high adequacy of the processes, usefulness of supplies and materials, efficient use in the different environments of the system; as a crucial information tool for the comparison and identification of the most cost-effective preventive interventions(AU)

Factors related to healthcare costs of road traffic accidents in Bucaramanga, Colombia / Factores relacionados con costos por atención médica de siniestros de tránsito en Bucaramanga, Colombia

ABSTRACT OBJECTIVE To determine the factors related to overall healthcare costs of road traffic accidents in Bucaramanga, Colombia. METHODS A descriptive cross-sectional study was conducted through the analysis of road traffic accident records that took place in 2019 in Bucaramanga, Colombia. Cost quartiles in dollars were compared using Pearson's chi-squared and Fisher's exact tests. Odds ratios were also calculated in logistic regression. RESULTS 3,150 road accidents were reported in 2019 involving 7,038 people, of which 812 had information related to healthcare costs in health care institutions. The median cost was 56.59 USD (RI = 29.35-140.15), average cost of 290.11 USD ± 731.22 (95%CI: 239.74-340.48). A higher possibility to be in the 4th quartile was found when persons were under 18 years of age (OR = 4.88; 95%CI: 1.30-18.32) or 46-60 years (OR = 3.66; 95%CI: 1.01-13.30), the type of vehicle involved is motorcycle (OR = 2.79; 95%CI: 1.25-6.24), bicycle (OR = 7.66; 95%CI: 2.70-21.68), having a head injury (OR = 4.50; 95%CI: 2.61-7.76) and hypothetical drunk driving (OR = 12.44; 95%CI: 2.01-76.87). CONCLUSIONS Relevant factors in healthcare costs were riding a motorcycle or bicycle, having a head injury, being under 18 years of age or 46 to 60 years of age and hypothetical drunk driving. It is important to implement prevention measures based on identified factors to reduce road accident rate and therefore, its socioeconomic costs.

RESUMEN OBJETIVO Determinar los factores relacionados con los costos generales durante la atención en salud de siniestros de tránsito en Bucaramanga, Colombia. MÉTODOS Estudio descriptivo, transversal, con análisis de registros de siniestros de tránsito durante 2019 en Bucaramanga, Colombia. Se realizó una comparación entre cuartiles de los costos en dólares con pruebas estadísticas de Chi-cuadrado de Pearson y exacta de Fisher. También, se calcularon odds ratio en regresión logística. RESULTADOS En 2019 se registraron 3.150 siniestros, con 7.038 personas involucradas, de los cuales 812 tenían información de costos generados por atención en instituciones de salud. La mediana de costos fue US$ 56,59 (RI = 29,35-140,15), promedio de US$ 290,11 ± 731,22 (IC95% 239,74-340,48). Se observó mayor posibilidad para estar en cuartil 4 de los costos si la persona tenía menos de 18 años (OR = 4,88; IC95% 1,30-18,32) o entre los 46-60 años de edad (OR = 3,66; IC95% 1,01-13,30), cuando el tipo de vehículo es la motocicleta (OR = 2,79; IC95% 1,25-6,24) y la bicicleta (OR = 7,66; IC95% 2,70-21,68), si la lesión ocurre en la cabeza (OR = 4,50; IC95% 2,61-7,76) y si la hipótesis está relacionada con embriaguez (OR = 12,44; IC95% 2,01-76,87). CONCLUSIÓN Los factores relevantes en los costos fueron la motocicleta, bicicleta, lesión en la cabeza, ser menor de 18 años o tener entre los 46 años y los 60 años y embriaguez como hipótesis. Es relevante implementar medidas de prevención según los factores identificados para disminuir la accidentalidad y, por ende, sus costos socioeconómicos.

A Brazilian cost-utility analysis of trabecular micro-bypass with iStent inject® for the treatment of open-angle glaucoma / Análise de custo-utilidade do implante trabecular iStent inject® para o tratamento do glaucoma de ângulo aberto no Brasil

ABSTRACT Purpose To evaluate the cost-utility of the iStent inject® for the treatment of mild-to-moderate open-angle glaucoma (OAG) within the Brazilian Unified Health System (SUS). Methods A Markov model was developed, in which the effectiveness outcome measure was the incremental cost-effectiveness ratio (ICER: R$ / QALY quality-adjusted life-year). Direct medical costs were obtained from the SUS perspective. The base case comprised of a hypothetical cohort of patients with OAG using topical medication and being managed according to the Clinical Protocol and Therapeutic Guidelines (PCDT) and a real-world setting based on data from Datasus. The model's robustness through sensitivity analyses was tested. Results In the PCDT base case setting, the trabecular micro-bypass implant provided gains of 0.47 QALYs and an ICER of R$7,996.66/QALY compared to treatment with topical medication. In the real-world setting based on data from Datasus, the trabecular micro-bypass implant, provided gains of 0.47 QALYs and an ICER of R$4,485.68/QALY compared to treatment with topical medication. The results were robust to sensitivity analyses. Conclusion Incorporating iStent inject® to SUS provides an improvement in the patient's quality of life with an additional cost that warrants the benefit provided to patients. Results may be considered cost-effective compared to topical medication.

RESUMO Objetivo Avaliar a relação custo-utilidade do iStent inject® para o tratamento do glaucoma de ângulo aberto leve a moderado no Sistema Único de Saúde. Métodos Foi desenvolvido um modelo de Markov, no qual a medida de resultado de efetividade foi a razão custo-efetividade incremental (razão de custo-efetividade incremental: R$/ano de vida ajustado pela qualidade). Os custos médicos diretos foram obtidos por meio da perspectiva do Sistema Único de Saúde. O caso base foi composto de uma coorte hipotética de pacientes com glaucoma de ângulo aberto em uso de medicação tópica tratados de acordo com o Protocolo Clínico e Diretrizes Terapêuticas e um cenário do mundo real baseado em dados do Departamento de Informática do Sistema Único de Saúde. Foi testada a robustez do modelo por meio de análises de sensibilidade. Resultados No cenário base do Protocolo Clínico e Diretrizes Terapêuticas, o implante trabecular micro-bypass proporcionou ganhos de 0,47 ano de vida ajustado pela qualidade e razão de custo-efetividade incremental de R$7.996,66/ano de vida ajustado pela qualidade em relação ao tratamento com medicação tópica. No cenário real baseado em dados do Departamento de Informática do Sistema Único de Saúde, o implante trabecular proporcionou ganhos de 0,47 ano de vida ajustado pela qualidade e razão de custo-efetividade incremental de R$ 4.485,68/ano de vida ajustado pela qualidade em relação ao tratamento com medicação tópica. Os resultados foram robustos para análises de sensibilidade. Conclusão A incorporação do iStent inject® ao Sistema Único de Saúde proporciona melhora na qualidade de vida do paciente com um custo adicional que garante o benefício proporcionado a eles. Os resultados podem ser considerados custo-efetivos em comparação com a medicação tópica.

Cost-utility analysis of traditional drug therapy with and without exercise program for hypertensive patients in real-life data primary health care

Abstract Aim: The study aimed to conduct a cost-utility analysis of traditional drug therapy (TDT) provided for hypertensive patients at primary care in comparison to the protocol based on combination with an exercise program (TDT+E) in real-life conditions, adopting a health system perspective. Methods: Longitudinal study based on enrollment of 49 hypertensive adults distributed into two groups, for 12 months. Quality-adjusted life years were estimated using health-related quality of life. Direct health care costs were calculated including inputs and human resources in primary care from medical records. Sensitivity analysis was performed based on multivariate and probabilistic scenarios. Results: Incremental cost-effectiveness ratios of TDT+E in comparison to TDT were +79.69. Sensitivity analysis showed that TDT+E presented advantages considering uncertainties. Conclusion: Our findings show that exercise programs may improve quality of life and life expectancy among hypertensive patients.

Process-based Management aimed at improving health care and financial results / Gestión basada en procesos visando a mejoría de los resultados asistenciales y financieros en Salud / Gestão baseada em processos visando à melhoria dos resultados assistenciais e financeiros em Saúde

ABSTRACT The limited resources allocated to the health area and the growing demands require leaders' qualified and committed performance in hospital management. In this perspective, the objective of this study is to reflect on the management practices that can be applied to hospital facilities to achieve better care and financial results. Among them, process-based management proposes an approach for continuous process improvement to achieve desired results; the method Lean Six Sigma allows identifying and eliminating waste in production processes; the continuous improvement model combines practical knowledge with the knowledge of how the system to be improved works, through observations and changes that allow its results measurement; and cost management and value-based healthcare provides for care mapping, from beginning to end, to assess what actually adds value to patients. The contributions of implementing these practices are recognized worldwide; using them, processes can be increased, improving efficiency, reducing waste, adding value to the business, increasing its revenue, and resulting in savings that can be passed on to the consumer, by improving quality.

RESUMEN Los recursos limitados destinados al área de Salud y las crecientes demandas exigen la actuación calificada y comprometida de líderes en la gestión hospitalaria. En esta perspectiva, el objetivo es reflexionar sobre las prácticas de gestión que se pueden aplicar a las instituciones hospitalarias para lograr mejores resultados asistenciales y económicos. Entre ellos, la gestión basada en procesos propone un enfoque de mejora continua de procesos para lograr los resultados deseados; el método Lean Six Sigma permite identificar y eliminar los desperdicios en los procesos productivos; el modelo de mejoría continua combina el conocimiento práctico al conocimiento del funcionamiento del sistema que se reta mejorar, a través de observaciones y cambios que permitan la medición de sus resultados; y la gestión de costes y de salud atención médica basada en el valor establece que la atención sea mapeada, desde el principio hasta el final del proceso, para evaluar lo que efectivamente es lo que agrega valor a los pacientes. Las contribuciones de implementación de esas prácticas son reconocidas a nivel mundial; con ellas se pueden incrementar los procesos, aumentando la eficiencia, reduciendo los desperdicios, agregando valor al negocio, aumentando sus ingresos y generando ahorros que pueden transferirse al consumidor, al mejorar la calidad.

RESUMO Os recursos limitados destinados à área da Saúde e as demandas crescentes requerem a atuação qualificada e compromissada dos líderes na gestão hospitalar. Nesta perspectiva, objetiva-se refletir sobre as práticas de gestão passíveis de serem aplicadas às instituições hospitalares visando o alcance de melhores resultados assistenciais e financeiros. Dentre elas, a gestão baseada em processos propõe uma abordagem para melhoria contínua dos processos a fim de alcançar os resultados desejados; o método Lean Six Sigma permite identificar e eliminar desperdícios nos processos produtivos; o modelo de melhoria contínua alia o conhecimento prático ao conhecimento do funcionamento do sistema a ser melhorado, por meio de observações e mudanças que permitam a mensuração de seus resultados; e a gestão de custos e a Saúde baseada em valor preveem que o cuidado seja mapeado, do início ao fim do processo, para avaliar o que, de fato, agrega valor aos pacientes. As contribuições da implementação dessas práticas são reconhecidas mundialmente; utilizando-as, os processos podem ser incrementados, aumentando a eficiência, reduzindo os desperdícios, agregando valor ao negócio, aumentando a sua receita e resultando em economias que podem ser repassadas ao consumidor, pela melhoria da qualidade.

Avaliação do processo psicoterápico: levantamento de técnicas e instrumentos / Assessment of the psychotherapeutic process: survey of techniques and instruments

Um dos aspectos mais estudados em intervenções psicoterápicas são os procedimentos empregados em psicoterapia que resultam em melhores benefícios ao paciente em um menor espaço de tempo, ou seja, a avaliação da eficiência do processo psicoterápico, prezando-se não apenas pela ética com o paciente, mas também pela redução de gastos com tratamentos. Diante disso, o objetivo deste estudo foi levantar quais os principais instrumentos utilizados com essa finalidade. Por meio de busca sistematizada de literatura, foram resgatados 5.938 artigos que, após triagem por meio de critérios de inclusão e exclusão, resultaram em um conjunto de 157 estudos analisados em sua íntegra, o que permitiu identificar 114 instrumentos e técnicas. Após a apresentação dos instrumentos mais recorrentes na literatura, algumas considerações foram tecidas a respeito do panorama atual de avaliação de processos psicoterapêuticos, como, por exemplo, a escassez de instrumentos brasileiros e as contribuições desta pesquisa para futuros estudos nessa temática.

One of the most studied aspects in psychotherapeutic interventions are the procedures used in psychotherapy that result in better patient benefits in a shorter period, the evaluation of psychotherapeutic process's efficiency, considering ethics toward the patient, and reducing treatment costs. This study aimed to identify the main instruments used for this purpose. Through a systematized review of literature, 5,938 articles were found, which, after screening by inclusion and exclusion criteria, resulted in a set of 157 studies and the identification of 114 instruments and techniques. After presenting the most recurrent instruments in the literature, some considerations were made regarding the current panorama of evaluation of psychotherapeutic processes, such as the scarcity of Brazilian instruments and the contributions of this research to future studies in this subject.

Caracterización clínica y de costos de la hospitalización asociada a varicela en niños de la Región Metropolitana y de Valparaíso, Chile / Clinical and cost characterization of hospitalization associated with varicella in children from the Metropolitan Region and Valparaíso, Chile

INTRODUCCIÓN: La varicela es una infección relevante en la salud pública de Chile, pudiendo causar en algunas ocasiones complicaciones graves e incluso la muerte, lo que se asocia a un significativo gasto en salud. En Chile sólo se realiza vigilancia centinela a nivel ambulatorio, sin conocerse el impacto de la varicela en casos más graves que determinan hospitalización. OBJETIVOS: Realizar una descripción clínica y de los costos asociados a la atención de niños hospitalizados con diagnóstico de varicela, en años previos a la introducción de la vacuna en el Programa Nacional de Inmunización en Chile. MATERIALES Y MÉTODOS: Estudio multicéntrico, observacional y retrospectivo, en todos los casos de niños hospitalizados (0-15 años) con diagnóstico de varicela, entre enero de 2011 y diciembre de 2015 en cinco hospitales de Chile. Se realizó revisión de fichas para evaluar características clínicas de la enfermedad y los costos asociados a la hospitalización por varicela. RESULTADOS: Un total de 685 hospitalizaciones por varicela fueron incluidas en el estudio. La mediana de edad fue de 3 años (RIC:1-5), siendo la mayoría de los niños con edades comprendidas entre los 1 y 4 años (52% del total de casos). El 56% fueron hombres y sólo 7 niño s (1%) tuvieron antecedente de vacuna varicela. La mediana de días de hospitalización fue de 3 días en cada episodio (RIC: 2-5). El 13% de los casos requirió hospitalización en unidades de mayor complejidad, 7% de los niños ingresó a Unidad de Tratamiento Intensivo y 6% ingresó a Intermedio, ambos con una mediana de 3 días de hospitalización. Las principales complicaciones fueron: infección de piel y tejidos blandos (42%), alteraciones neurológicas (8%) y shock séptico/tóxico (4%). La letalidad fue de 0,4%. El costo de un caso de varicela considerando los costos directos fue de US$417, el costo indirecto fue de US$224 y los costos proporcionales de una muerte de US$3.575. Se estima que el costo total de un caso de varicela hospitalizado en Chile, considerando todos los factores anteriores, fue de US$4.216. CONCLUSIONES: La varicela es una enfermedad inmunoprevenible frecuente. Se observaron casos con una mediana de 3 días de hospitalización por complicaciones, con 13% de los casos requiriendo hospitalización en unidades de mayor complejidad, con un alto costo asociado, que se estima podría disminuir significativamente con la reciente incorporación de la vacuna al Programa Nacional de Inmunizaciones.

BACKGROUND: Varicella is a relevant infection in Chile and may cause serious complications and death, which could be associated with significant health care resource utilization and associated costs. In Chile, sentinel surveillance is carried out only on an outpatient basis, without knowing the impact of varicella in serious cases who need to be hospitalized. AIM: To describe the clinical characteristics and the costs associated with hospitalized children with diagnosis of varicella prior to the vaccine introduction in the National Immunization Program in Chile. PATIENTS AND METHODS: A multicenter, observational, and retrospective study in hospitalized children (0-15 years) with a diagnosis of varicella, were conducted in five hospitals in Chile between January 2011 and December 2015. A review of the clinical records was performed to evaluate the clinical characteristics of the disease and costs associated with hospitalization episodes for varicella. RESULTS: A total of 685 hospitalized children for varicella were included in this study. The median age was 3 years (IQR: 1-5), most children were between 1 and 4 years of age (52% of total cases). 56% were male, and only 7 patients (1%) had a history of previous varicella vaccination. The median lenght of days of hospitalization was 3 days (IQR: 2-5). 13% of the cases required hospitalization in a more complex care unit, 6% in the intermediate unit and 7% in the pediatric intensive treatment unit, both with a median stay of 3 days. The main complications were: skin and soft tissue infections (42%), neurologic (8%) and septic or toxic shock (4%). There were 3 cases of death (0.4%). The direct cost of a varicella case was US $ 417, the indirect cost was US $ 224 and the proportional cost of a case of death was US $ 3,575. It is estimated that the total cost of a hospitalized varicella case in Chile was US $ 4,216. CONCLUSIONS: Varicella is associated with a significant burden of disease in Chile. The median hospital stay was three days with 13% of cases requiring medical care in a complex unit, with high associated costs which could be significantly reduced with the recently incorporation of the varicella vaccine into the National Immunization Program.

Simulación de intubación pediátrica con videolaringoscopio de bajo costo en contexto de pandemia por COVID-19 / Simulation of pediatric intubation using a low-cost videolaryngoscope in the setting of the COVID-19 pandemic

En pacientes con infección por SARS-CoV-2 la intubación endotraqueal es un procedimiento con riesgo elevado de contagio. La videolaringoscopia complementa la protección del profesional, pero los videolaringoscopios comerciales son caros y no siempre están disponibles en las terapias intensivas pediátricas argentinas. El objetivo fue describir la práctica de intubación en un modelo de cabeza de simulación de lactante con un videolaringoscopio artesanal de bajo costo.Quince pediatras sin experiencia previa con el dispositivo participaron de una práctica de intubación en una cabeza de simulación con un videolaringoscopio artesanal. El tiempo promedio del primer intento fue de 116,4 segundos (intervalo de confianza del 95 % [IC95 %]: 84,8-148,0) y, el del siguiente fue de 44,2 segundos (IC95 %: 27,7­60,6). El tiempo disminuyó de forma significativa en el segundo intento (p : 0,0001). El dispositivo permitió la intubación exitosa en todos los intentos acortando la duración del procedimiento en la segunda práctica

In patients with SARS-CoV-2 infection, endotracheal intubation is a procedure with a high risk for transmission. A videolaryngoscopy is a supplementary level of health care provider protection, but commercial videolaryngoscopes are expensive and not always available in pediatric intensive care units in Argentina. Our objective was to describe intubation practice using an infant head mannequin with a low-cost, handcrafted videolaryngoscope.Fifteen pediatricians with no prior experience using the device participated in an intubation practice in a head mannequin with a handcrafted videolaryngoscope. The average time for the first attempt was 116.4 seconds (95 % confidence interval [CI]: 84.8-148.0) and, for the second one, 44.2 seconds (95 % CI: 27.7-60.6). Time decreased significantly for the second attempt (p: 0.0001).A successful intubation was achieved with the device in all attempts, and the procedure duration decreased with the second practice

Custo anual de cuidado ao paciente segundo o tipo de morbidade / Annual cost of health care according to individual morbidity

Objetivo: O objetivo deste estudo foi o de conhecer os custos da utilização do serviço público de saúde por indivíduos segundo suas morbidades crônicas. Métodos: A metodologia adotada para apuração dos custos foi o sistema de custeio por absorção. Os custos apurados para cada serviço foram cruzados com a base de dados dos usuários atendidos no mesmo período, incluindo um conjunto de condições de saúde ou doença existentes, sem identificação dos usuários. Resultados: Os resultados obtidos correspondem aos custos de 375.760 usuários que utilizaram algum serviço da rede municipal de saúde durante o período de um ano. Os custos variaram de R$ 0,05 a R$ 16.773,82, sendo os menores equivalentes apenas ao consumo de medicamentos e os maiores, ao uso de múltiplos serviços. Conclusão: O estudo demonstrou importante variação nos custos médios por indivíduo no contexto de uma rede municipal de saúde estruturada, com associação direta ao problema/condição de saúde observado

Objective: The aim of this study was to know the costs of public health service users in a Brazilian city, according to their chronic morbidities. Methods: Cost method absortion was the methodology adopted to calculate those costs. The costs of each service were cross-referenced with a database of users cared in the same period, including a set of pre-existing health conditions, with no individual identification. Results: The results obtained correspond to the costs of 375,760 individuals who use some service of the municipal health network for a year. Costs ranged from R$ 0.05 to R$ 16,773.82, the lowest were equivalent to the consumption of medicines only and the highest to the use of multiple services. Conclusion: Significant variation was observed in the average costs per individual directly associated with the health problem/condition

Direct healthcare costs and their relationships with age at start of drug use and current pattern of use: a cross-sectional study

ABSTRACT BACKGROUND: It is well known that early start of drug use can lead users to psychosocial problems in adulthood, but its relationship with users' direct healthcare costs has not been well established OBJECTIVES: To estimate the direct healthcare costs of drug dependency treated at a community mental health service, and to ascertain whether early start of drug use and current drug use pattern may exert influences on these costs. DESIGN AND SETTING: Retrospective cross-sectional study conducted at a community mental health service in a municipality in the state of São Paulo, Brazil. METHODS: The relationships between direct healthcare costs from the perspective of the public healthcare system, age at start of drug use and drug use pattern were investigated in a sample of 105 individuals. A gamma-distribution generalized linear model was used to identify the cost drivers of direct costs. RESULTS: The mean monthly direct healthcare costs per capita for early-start drug users in 2020 were 1,181.31 Brazilian reais (BRL) (274.72 United State dollars (USD) according to purchasing power parity (PPP)) and 1,355.78 BRL (315.29 USD PPP) for late-start users. Early start of drug use predicted greater severity of cannabis use and use of multiple drugs. The highest direct costs were due to drug dependence combined with alcohol abuse, and due to late start of drug use. CONCLUSIONS: Preventive measures should be prioritized in public policies, in terms of strengthening protective factors before an early start of drug use.

Cost-benefit analysis of drinking water fluoridation in 12-year-old children in the Biobío region, Chile / Análisis costo-ceneficio de la fluoración del agua potable en niños de12 años de la región del Biobío, Chile

Fluoridation has been shown to be an effective measure against caries in children. The present study evaluates the cost-benefit of the fluoridated water program for the reduction of dental caries in 12-year-old children in the Biobío Region, the only region in Chile that has not implemented this program. An economic cost-benefit evaluation was carried out, comparing two alternative interventions: non-fluoridated drinking water versus fluoridated drinking water. The prevalence of caries, direct and indirect costs of the treatments, the cost of implementing the programs and the benefits of both interventions were estimated. From this study it is concluded that the savings in oral health costs in 12-year-old children when using fluoridating drinking water in the Biobío region is significantly higher than the cost involved in implementing the water fluoridation program, resulting in total savings for the Chilean state of $129,861,645 (USD$ 152,833) as well as an estimated reduction of 15% in the history of caries in the study population.

Se ha demostrado que la fluoración es una medida efectiva contra disminución de la caries en la población infantil. La presente investigación buscó evaluar cual es el costo-beneficio del programa del agua fluorada para la disminución de caries dental en niños de 12 años de la Región del Biobío, única región de Chile que no adhiere a este programa. Se realizó una evaluación económica de costo-beneficio, comparando dos intervenciones alternativas: agua potable no fluorada versus agua potable fluorada. Para tal fin se estimó la prevalencia de caries, costos directos e indirectos de los tratamientos, el costo de implementación de los programas y el beneficio de ambas intervenciones. De este estudio se concluye que el ahorro en costos de salud bucal en niños de 12 años al fluorar el agua potable en la región del Biobío, es significativamente mayor al costo que implica la implementación del programa de fluoración de aguas, lográndose un ahorro total para el Estado de $129.861.645 (USD $152.833) así como una estimación de reducción del 15% en la historia de caries en la población de estudio.

Experiências das mulheres quanto às suas trajetórias até o diagnóstico de endometriose / Experiencias de mujeres en cuanto a sus trayectorias hasta el diagnóstico de endometriosis / Experiences of women regarding their pathways to the diagnosis of endometriosis

Resumo Objetivo descrever as experiências das mulheres sobre as suas trajetórias desde o início dos sintomas até o diagnóstico da endometriose. Método pesquisa descritiva, qualitativa, realizada com dez mulheres com diagnóstico de endometriose no município do Rio de Janeiro (RJ), Brasil. Coletaram-se entrevistas semiestruturadas áudio gravadas e posteriormente submetidas à Análise de Conteúdo por meio do software Atlas.ti 8. Resultados sem o diagnóstico de endometriose, as mulheres vivenciam sintomas fortes desde a menarca. Essa situação repercute negativamente em diferentes esferas da vida, inclusive pela desvalorização de suas queixas em seus círculos de convivência. Assim, entende-se a importância da rede de apoio perante essa situação. Diante desse contexto, as mulheres peregrinam por diversos profissionais até o diagnóstico definitivo. Considerações finais e implicações para a prática as trajetórias dessas mulheres são marcadas pela desvalorização de suas queixas por profissionais de saúde e pessoas próximas, pela naturalização da dor feminina e pela dificuldade em estabelecer um diagnóstico diferencial. No entanto, a capacidade individual de reconhecer a presença de uma patologia, o conhecimento sobre a endometriose e a experiência do profissional facilitaram o diagnóstico. No contexto da assistência de enfermagem, entender essa trajetória pode promover a escuta ativa, melhor valorização das queixas, avaliação clínica e o encaminhamento para o diagnóstico precoce.

Resumen Objetivo describir las vivencias de las mujeres en sus trayectorias desde el inicio de los síntomas hasta el diagnóstico de endometriosis. Método investigación descriptiva cualitativa realizada con diez mujeres diagnosticadas con endometriosis en la ciudad de Río de Janeiro (RJ), Brasil. Se recogieron entrevistas semiestructuradas grabadas en audio y posteriormente se sometieron a Análisis de Contenido utilizando el software Atlas.ti 8. Resultados sin el diagnóstico de endometriosis, las mujeres experimentan síntomas fuertes desde la menarquia. Esta situación tiene un impacto negativo en diferentes ámbitos de la vida, incluso por la devaluación de sus quejas en sus círculos de convivencia. Así, se comprende la importancia de la red de apoyo en esta situación. Ante este contexto, las mujeres deambulan por diferentes profesionales hasta el diagnóstico definitivo. Consideraciones finales e implicaciones para la práctica las trayectorias de estas mujeres están marcadas por la devaluación de sus quejas por parte de los profesionales de la salud y personas cercanas, por la naturalización del dolor femenino y por la dificultad para establecer un diagnóstico diferencial. Sin embargo, la capacidad del individuo para reconocer la presencia de una patología, el conocimiento sobre la endometriosis y la experiencia del profesional facilitaron el diagnóstico. En el contexto del cuidado de enfermería, comprender esta trayectoria puede promover la escucha activa, mejor valoración de las quejas, evaluación clínica y la derivación para diagnóstico precoz.

Abstract Objectives to describe the experiences of women on their trajectories from the beginning of symptoms to the diagnosis of endometriosis. Method descriptive, qualitative research, conducted with ten women diagnosed with endometriosis in the city of Rio de Janeiro (RJ), Brazil. Audio recorded semi-structured interviews were collected and later submitted to Content Analysis using Atlas.ti 8 software. Results without the diagnosis of endometriosis, women experience strong symptoms from the menarche. This situation has a negative impact on different spheres of life, including the devaluation of their complaints in their circles of coexistence. Thus, the importance of the support network in this situation is understood. Faced with this context, women wander through various professionals until the definitive diagnosis. Final considerations and implications for practice the trajectories of these women are marked by the devaluation of their complaints by health professionals and people close to them, by the naturalization of female pain and by the difficulty in establishing a differential diagnosis. However, the individual's ability to recognize the presence of a pathology, the knowledge about endometriosis and the professional's experience facilitated the diagnosis. In the context of nursing care, understanding this trajectory can promote active listening, better appreciation of complaints, clinical assessment and referral to early diagnosis.

Immunotherapy-based first-line treatment of intermediate- and poor-risk advanced renal cell carcinoma: number needed to treat and cost of preventing an event from the perspective of the Brazilian private healthcare system / Tratamento baseado em imunoterapia para primeira linha do carcinoma renal avançado com risco intermediário ou alto: número necessário a tratar e custo para prevenir um evento na perspectiva do sistema privado de saúde brasileiro

Objective: To perform an analysis over time of the number needed to treat (NNT) and the cost of preventing an event (COPE) for nivolumab + ipilimumab (NIVO+IPI) and pembrolizumab + axitinib (PEMBRO+AXI) as first-line treatments for advanced renal cell carcinoma patients with intermediate or poor-risk, under the Brazilian private healthcare system perspective. Methods: The NNT for overall survival (OS) and progression-free survival (PFS) from 12-month to maximum available follow-up from CheckMate 214 and KEYNOTE-426 studies were used to estimate the COPE. Treatment costs were estimated considering the labeled dosing and median PFS as a proxy for treatment duration. Results: The OS NNT for NIVO+IPI decreased from 12 to 8 and for PEMBRO+AXI increased slightly from 7 to 8 at 12 and 42 months, respectively. For PFS, NNT for NIVO+IPI decreased from 15 to 6, and for PEMBRO+AXI increased from 7 to 10 at 12 and 30 months. The estimated treatment cost is R$ 638,620 for an estimated median of 11.2 months of NIVO+IPI treatment and R$ 966,818 for 13.8 months of PEMBRO+AXI treatment. COPE for OS at 12 and 42 months was R$ 7,663,440 and R$ 5,108,960 with NIVO+IPI and R$ 6,047,417 and R$ 7,734,547 with PEMBRO+AXI. For PFS, COPE at 12 and 30 months was R$ 9,579,300 and R$ 3,831,720 with NIVO+IPI and R$ 6,047,417 and R$ 9,668,184 with PEMBRO+AXI. Conclusions: Treatment with NIVO+IPI results in lower COPE than PEMBRO+AXI from month 18 onwards, driven by lower treatment costs and improved NNT over time with NIVO+IPI

Objetivo: Analisar ao longo do tempo o número necessário a tratar (NNT) e o custo para prevenir um evento (COPE) para nivolumabe + ipilimumabe (NIVO+IPI) e pembrolizumabe + axitinibe (PEMBRO+AXI) na primeira linha de tratamento do carcinoma de células renais avançado com risco intermediário ou alto na perspectiva do sistema suplementar de saúde brasileiro. Métodos: O NNT para sobrevida global (SG) e sobrevida livre de progressão (SLP) para 12 meses até o máximo de tempo de seguimento disponível dos estudos CheckMate 214 e KEYNOTE-426 foi usado para estimar o COPE. Custos de tratamento foram estimados considerando a dosagem em bula e a mediana de SLP como aproximação para duração de tratamento. Resultados: O NNT de SG para NIVO+IPI reduziu de 12 para 8 e para PEMBRO+AXI subiu de 7 para 8 em 12 e 42 meses, respectivamente. Para SLP, NIVO+IPI teve redução de 15 para 6 e para PEMBRO+AXI aumentou de 7 para 10 em 12 e 30 meses. O custo estimado é de R$ 638.620 para mediana de 11,2 meses de tratamento com NIVO+IPI e de R$ 966.818 para 13,8 meses com PEMBRO+AXI. O COPE para SG foi de R$ 7.663.440 e R$ 5.108.960 com NIVO+IPI e de R$ 6.047.417 e R$ 7.734.547 com PEMBRO+AXI para 12 e 42 meses. Para SLP, foi de R$ 9.579.300 e R$ 3.831.720 com NIVO+IPI e de R$ 6.047.417 e R$ 9.668.184 com PEMBRO+AXI em 12 e 30 meses. Conclusões: O tratamento com NIVO+IPI resulta em menor COPE, em comparação com PEMBRO+AXI, a partir de 18 meses de seguimento, justificado por menor custo de tratamento e melhora do NNT ao longo do tempo com NIVO+IPI